BioNTech is a German biotechnology company that focuses on developing and manufacturing messenger RNA (mRNA) therapeutics and vaccines. Founded in 2008, its primary aim is to harness the body’s immune system to respond against diseases such as cancer and infectious diseases. BioNTech gained international prominence for its collaborative development of an mRNA-based vaccine against COVID-19, in partnership with Pfizer, which was one of the first vaccines authorized for emergency use to combat the pandemic. The company is known for its innovative approach in utilizing mRNA technology, which provides instructions for cells to produce proteins that can trigger immune responses.
BioNTech faces reduced profits and revenues after pandemic vaccine demand subsides. The company reported a net loss of approximately €700 million in 2024 with income per share at €1.08. Future…